Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STAA
STAA logo

STAA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy STAAR Surgical Co (STAA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
29.120
1 Day change
-0.34%
52 Week Range
35.870
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

STAAR Surgical Co (STAA) does not present a strong buy opportunity at this moment for a beginner investor with a long-term strategy. While the company has shown strong Q1 results and positive developments in China, the lack of forward guidance, neutral trading sentiment, and absence of significant technical or proprietary trading signals make it prudent to hold off on investing right now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 47.841, and moving averages are converging, suggesting no clear trend. Key support is at 28.375, and resistance is at 30.575. The stock's technical indicators do not provide a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
5

Positive Catalysts

  • Positive sentiment around potential valuation re-rating and growth in China.

Neutral/Negative Catalysts

  • Management has refrained from providing FY26 guidance, limiting visibility into future performance. Neutral trading sentiment from hedge funds and insiders. No recent news or significant event-driven catalysts.

Financial Performance

No detailed financial data available for analysis. However, Q1 results exceeded expectations, with strong performance in China and double-digit growth in the Americas.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally positive, with several raising price targets and upgrading ratings. However, some maintain Neutral ratings, citing limited visibility into future guidance.

Wall Street analysts forecast STAA stock price to rise
3 Analyst Rating
Wall Street analysts forecast STAA stock price to rise
0 Buy
3 Hold
0 Sell
Hold
Current: 29.220
sliders
Low
30.75
Averages
30.75
High
30.75
Current: 29.220
sliders
Low
30.75
Averages
30.75
High
30.75
Mizuho
Anthony Petrone
Neutral
maintain
$22 -> $27
AI Analysis
2026-05-14
Reason
Mizuho
Anthony Petrone
Price Target
$22 -> $27
AI Analysis
2026-05-14
maintain
Neutral
Reason
Mizuho analyst Anthony Petrone raised the firm's price target on Staar Surgical to $27 from $22 and keeps a Neutral rating on the shares. The company's Q1 results were well ahead of expectations, the analyst tells investors in a research note. However, the firm says no guidance was issued as visibility still remains limited.
Wedbush
Neutral
to
Outperform
upgrade
$26 -> $40
2026-05-14
Reason
Wedbush
Price Target
$26 -> $40
2026-05-14
upgrade
Neutral
to
Outperform
Reason
Wedbush upgraded Staar Surgical to Outperform from Neutral with a price target of $40, up from $26. The Q1 report brings confidence that Staar is either at or nearing an inflection point for a full China rebound, the analyst tells investors in a research note. Wedbush says it is taking a longer-term view to the Staar Surgical story. It would \"rather be early than late\" as the firm believes the company has the potential to exceed even its bull case scenario in the coming quarters. Further China recovery progress is likely to lead to valuation re-rating and multiple expansion to historical levels, Wedbush contends.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STAA
Unlock Now

People Also Watch